Bayer CEO Bill Anderson Faces 21% Salary Cut to €8.84 Million Amid Restructuring

Bayer's CEO, Bill Anderson, has seen his total compensation drop to approximately €8.84 million ($9.6 million) for 2024, marking a 21% decrease compared to the previous year. This decline comes as part of a significant corporate restructuring initiated by the German conglomerate.

The salary reduction was somewhat anticipated, given that €3.8 million of Anderson's 2023 compensation was a one-time "compensation payment" he received for transitioning from his role at Roche to Bayer. In 2023, his total compensation was €11.24 million.

In examining Anderson's 2024 pay structure, his base salary remains unchanged at €2.25 million. However, he has seen an increase in earnings from both short-term and long-term stock incentives, which amount to approximately €2 million and €3.6 million, respectively.

The Bayer compensation committee acknowledged that "2024 is a highly challenging year," emphasizing that it marks the beginning of a three-year restructuring period for the company. Anderson officially joined Bayer in April 2023, succeeding Werner Baumann, and rapidly initiated extensive restructuring efforts aimed at revitalizing the pharmaceutical product line and addressing ongoing litigation in the U.S.

Recent reports indicate that while Bayer's consumer health and crop science divisions continue to experience revenue declines in the fourth quarter and for the year, the pharmaceutical segment saw a modest sales increase of 1.7% in Q4 and 0.3% for the year. However, with the anticoagulant Xarelto facing increased competition from generics, the company warns that no significant growth in the pharmaceutical business is expected before 2027.

Bayer is also dealing with numerous lawsuits stemming from its $63 billion acquisition of Monsanto in 2018, which involved claims that Monsanto's herbicide Roundup causes cancer. To manage these legal expenses, Bayer plans to seek shareholder approval for a potential stock issuance of up to 35% of its outstanding shares to help cover litigation and settlement costs.